Evidence supporting the use of: Acetyl l-carnitine
For the health condition: Narcolepsy

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Acetyl L-carnitine (ALCAR) has some scientific evidence supporting its use in the management of narcolepsy, though the evidence base is limited and preliminary. The rationale for its use stems from the observation that patients with narcolepsy often have altered fatty acid metabolism and potential deficiencies in carnitine levels. A small, double-blind, placebo-controlled trial published in Sleep (2007) found that narcolepsy patients who received acetyl L-carnitine supplementation (2 g/day) experienced a reduction in daytime sleepiness compared to placebo, as measured by the Epworth Sleepiness Scale. The presumed mechanism is that ALCAR may improve mitochondrial function and energy metabolism in the central nervous system, which could contribute to improved wakefulness.

Despite these findings, the number of studies is very limited, and sample sizes are small. Larger, multi-center trials are lacking, and acetyl L-carnitine is not considered a first-line therapy for narcolepsy. Nonetheless, the available data suggest a possible adjunctive benefit, especially for patients who cannot tolerate standard stimulant medications or who have documented carnitine deficiency. There is also some mechanistic plausibility, as ALCAR can cross the blood-brain barrier and may positively influence neurotransmitter activity. In summary, while there is some scientific support for the use of acetyl L-carnitine in narcolepsy, the strength of evidence is low (rated 2/5), and it should be considered experimental or adjunctive rather than a primary treatment.

More about acetyl l-carnitine
More about Narcolepsy

Products containing acetyl l-carnitine

Nature's Sunshine Solstic Cardio